Bacillus Calmette–Guérin strain differences as the basis for immunotherapies against bladder cancer

International Journal of Urology

Volumn 25, Issue 5, 2018, Pages 405-413

  Miyazaki, Jun ^a   Onozawa, Mizuki ^a   Takaoka, Eiichiro ^a   Yano, Ikuya ^b  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

bacillus Calmette Gu rin vaccine; bladder cancer; immunotherapy; Mycobacterium bovis bacillus Calmette Gu rin; strain differences

Indexed keywords

ADVERSE OUTCOME; BACTERIAL STRAIN; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL OUTCOME; GENETIC DIFFERENCE; HUMAN; IMMUNE RESPONSE; MEDICAL HISTORY; MYCOBACTERIUM BOVIS BCG; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; TREATMENT RESPONSE; BLADDER TUMOR; GENETICS; HISTORY; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; MYCOBACTERIUM BOVIS; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE;

BCG VACCINE; CYTOKINE;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CYTOKINES; HISTORY, 20TH CENTURY; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM BOVIS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85043257811     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.13538     Document Type: Review

References (72)

1. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 1996; 178: 1274–82.
2. Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine 1999; 17: 915–22.
3. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 1991; 262: 3–11.
4. Nauts HC, McLaren JR. Coley toxins–the first century. Adv. Exp. Med. Biol. 1990; 267: 483–500.
5. Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 1959; 184(Suppl 5): 291–2.
6. Nathanson L. Use of BCG in the treatment of human neoplasms: a review. Semin. Oncol. 1974; 1: 337–50.
7. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 1976; 116: 180–3.
8. Sylvester RJ, dervan MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 1964–70.
9. Malmstrom PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 2009; 56: 247–56.
10. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 2011; 59: 997–1008.
11. Perera M, Papa N, Christidis D et al. The impact of the global BCG shortage on treatment patterns: population-based data. BJU Int. 2018; 121: 169–72.
12. Gan C, Mostafid H, Khan MS, Lewis DJ. BCG immunotherapy for bladder cancer–the effects of substrain differences. Nat. Rev. Urol. 2013; 10: 580–8.
13. Mathe G, Amiel JL, Schwarzenberg L et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1969; 1: 697–9.
14. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970; 68: 158–63.
15. Martinez-Pineiro JA, Muntanola P. Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report. Eur. Urol. 1977; 3: 11–22.
16. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J. Urol. 1980; 124: 38–40.
17. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 1991; 325: 1205–9.
18. Fomukong NG, Dale JW, Osborn TW, Grange JM. Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. J. Appl. Bacteriol. 1992; 72: 126–33.
19. Harboe M, Nagai S, Patarroyo ME, Torres ML, Ramirez C, Cruz N. Properties of proteins MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect. Immun. 1986; 52: 293–302.
20. Li H, Ulstrup JC, Jonassen TO, Melby K, Nagai S, Harboe M. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect. Immun. 1993; 61: 1730–4.
21. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520–3.
22. Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 1999; 32: 643–55.
23. Belley A, Alexander D, Di Pietrantonio T et al. Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines. Infect. Immun. 2004; 72: 2803–9.
24. Mostowy S, Tsolaki AG, Small PM, Behr MA. The in vitro evolution of BCG vaccines. Vaccine 2003; 21: 4270–4.
25. Lewis KN, Liao R, Guinn KM et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J. Infect. Dis. 2003; 187: 117–23.
26. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 2002; 46: 709–17.
27. Behr MA, Small PM. Has BCG attenuated to impotence? Nature 1997; 389: 133–4.
28. Brosch R, Gordon SV, Garnier T et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. U S A. 2007; 104: 5596–601.
29. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob. Agents Chemother. 2009; 53: 316–8.
30. Malhotra P, Farber BF. Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections. Can. J. Urol. 2011; 18: 5671–5.
31. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat. Rev. Urol. 2014; 11: 153–62.
32. Poggi MM, Johnstone PA, Conner RJ. Glycosaminoglycan content of human bladders. a method of analysis using cold-cup biopsies. Urol Oncol. 2000; 5: 234–7.
33. Hudson MA, Ritchey JK, Catalona WJ, Brown EJ, Ratliff TL. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res. 1990; 50: 3843–7.
34. Secanella-Fandos S, Luquin M, Julian E. Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains. J. Urol. 2013; 189: 711–8.
35. Chen JM, Islam ST, Ren H, Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 2007; 25: 8114–22.
36. Naka T, Maeda S, Niki M et al. Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain. J. Biol. Chem. 2011; 286: 44153–61.
37. Kremer LS, Besra GS. Current status and future development of antitubercular chemotherapy. Expert Opin. Investig. Drugs 2002; 11: 1033–49.
38. Dubnau E, Chan J, Raynaud C et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. 2000; 36: 630–7.
39. Fujita Y, Okamoto Y, Uenishi Y, Sunagawa M, Uchiyama T, Yano I. Molecular and supra-molecular structure related differences in toxicity and granulomatogenic activity of mycobacterial cord factor in mice. Microb. Pathog. 2007; 43: 10–21.
40. Behr MA, Schroeder BG, Brinkman JN, Slayden RA, Barry CE 3rd. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. J. Bacteriol. 2000; 182: 3394–9.
41. Hayashi D, Takii T, Fujiwara N et al. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol. Med. Microbiol. 2009; 56: 116–28.
42. ® The BCG strain used makes a difference!. J. Urol. 2012; 187: e676.
43. Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K. A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J. Urol. 2013; 190: 50–4.
44. Rentsch CA, Birkhauser FD, Biot C et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur. Urol. 2014; 66: 677–88.
45. Fellows GJ, Parmar MK, Grigor KM, Hall RR, Heal MR, Wallace DM. Marker tumour response to Evans and Pasteur bacille Calmette-Guerin in multiple recurrent pTa/pT1 bladder tumours: report from the medical research council subgroup on superficial bladder cancer (Urological cancer working party). Br. J. Urol. 1994; 73: 639–44.
46. Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch south east cooperative urological group. Semin. Urol. Oncol. 1996; 14: 10–6.
47. Witjes JA, Dalbagni G, Karnes RJ et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol. Oncol. 2016; 34: e19–25.
48. Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS. Efficacy of Bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J. Urol. 2017; 198: 503–10.
49. Hinotsu S, Kamatani N, Ratliff TL, Akaza H. A systematic review and meta-analysis on the safety and efficacy of different strains of Mycobacterium bovis bacillus Calmette–Guerin for non-muscle invasive bladder cancer in Japan and US. Eur. J. Oncol. Pharm. 2014; 8: 8–18.
50. Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. J. Urol. 2005; 173: 1507–12.
51. Hesseling AC, Schaaf HS, Hanekom WA et al. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin. Infect. Dis. 2003; 37: 1226–33.
52. Bonifachich E, Chort M, Astigarraga A et al. Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina. Vaccine 2006; 24: 2894–9.
53. Liu J, Tran V, Leung AS, Alexander DC, Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Human Vaccin. 2009; 5: 70–8.
54. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 2003; 169: 90–5.
55. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J. Urol. 2001; 166: 476–81.
56. Lamm DL, Blumenstein BA, David Crawford E et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol. Oncol. 1995; 1: 119–26.
57. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol. Clin. North Am. 1992; 19: 565–72.
58. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J. Urol. 1986; 135: 272–4.
59. Elkabani M, Greene JN, Vincent AL, VanHook S, Sandin RL. Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer. Cancer Control 2000; 7: 476–81.
60. Tektonidou MG. Reiter's syndrome during intravesical BCG therapy for bladder carcinoma. Clin. Rheumatol. 2007; 26: 1368–9.
61. Miyazaki J, Hinotsu S, Ishizuka N et al. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. Jpn. J. Clin. Oncol. 2013; 43: 827–34.
62. Kato T, Bilim V, Yuuki K et al. Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro. Anticancer Res. 2010; 30: 4089–96.
63. Joraku A, Homhuan A, Kawai K et al. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guerin. BJU Int. 2009; 103: 686–93.
64. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013; 104: 22–7.
65. Nakamura T, Fukiage M, Higuchi M et al. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J. Control. Release 2014; 176: 44–53.
66. Miyazaki J, Nishiyama H, Yano I et al. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res. 2011; 31: 2065–71.
67. Li R, Amrhein J, Cohen Z, Champagne M, Kamat AM. Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Bladder Cancer 2017; 3: 65–71.
68. Douglass L, Schoenberg M. The future of intravesical drug delivery for non-muscle invasive bladder cancer. Bladder Cancer. 2016; 2: 285–92.
69. Donin NM, Lenis AT, Holden S et al. Immunotherapy for the treatment of urothelial carcinoma. J. Urol. 2017; 197: 14–22.
70. Dinney CP, Fisher MB, Navai N et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J. Urol. 2013; 190: 850–6.
71. Katz H, Wassie E, Alsharedi M. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Med. Oncol. 2017; 34: 170.
72. Siddiqui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials in non-muscle invasive bladder cancer. Urol. Oncol. 2017; 35: 516–27.